These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31504352)

  • 21. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
    Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
    Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
    Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
    Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
    Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
    Huang DQ; Tamaki N; Lee HW; Park SY; Lee YR; Lee HW; Lim SG; Lim TS; Kurosaki M; Marusawa H; Mashiba T; Kondo M; Uchida Y; Kobashi H; Furuta K; Izumi N; Kim BK; Sinn DH
    Hepatology; 2023 May; 77(5):1746-1756. PubMed ID: 36633913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis.
    Jang JW; Choi JY; Kim YS; Woo HY; Choi SK; Lee CH; Kim TY; Sohn JH; Tak WY; Han KH
    Hepatology; 2015 Jun; 61(6):1809-20. PubMed ID: 25627342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
    Wei Q; Xu X; Ling Q; Zhou B; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):251-5. PubMed ID: 23742769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.
    Wang W; Tian SL; Wang H; Shao CC; Wang YZ; Li YL
    JAMA Netw Open; 2020 Apr; 3(4):e203707. PubMed ID: 32338753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study.
    Dan JQ; Zhang YJ; Huang JT; Chen MS; Gao HJ; Peng ZW; Xu L; Lau WY
    Eur J Surg Oncol; 2013 Aug; 39(8):865-72. PubMed ID: 23597497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
    An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis.
    Kong J; Liang X; Zhang J; Zeng J; Liu J; Zeng J
    Dig Dis Sci; 2022 Aug; 67(8):4250-4257. PubMed ID: 34523084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels.
    Lee J; Sinn DH; Kim JH; Gwak GY; Kim HS; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    J Korean Med Sci; 2015 Nov; 30(11):1618-24. PubMed ID: 26539006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.
    Lee H; Jang S; Ahn SH; Kim BK
    Hepatol Int; 2022 Apr; 16(2):294-305. PubMed ID: 35322374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.
    Wang P; Wang X; Liu X; Yan F; Yan H; Zhou D; Yu L; Wang X; Yang Z
    BMC Cancer; 2023 Jun; 23(1):564. PubMed ID: 37340357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and survival analysis of patients with hepatocellular carcinoma after hepatitis B virus turning negative.
    Li H; Guo WM; Xie Q; Sun X; Wang Q
    Adv Clin Exp Med; 2022 Jul; 31(7):731-738. PubMed ID: 35302303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral therapy and long-term outcome for hepatitis B virus-related hepatocellular carcinoma after curative liver resection in a Japanese cohort.
    Sakamoto K; Beppu T; Hayashi H; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Isiko T; Kikuchi K; Baba H
    Anticancer Res; 2015 Mar; 35(3):1647-55. PubMed ID: 25750323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
    Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
    Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
    Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.
    Jeon MY; Kim BK; Lee JS; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Clin Mol Hepatol; 2021 Apr; 27(2):295-304. PubMed ID: 33317247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.